WallStreetZenWallStreetZen

NASDAQ: MDXG
Mimedx Group Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Mimedx Group earnings were $30.7M for the trailing 12 months ending Mar 31, 2026, with -22.2% growth year over year. The latest MDXG earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$10.9M, down 171.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MDXG reported annual earnings of $48.6M, with 14.5% growth. The next MDXG earnings date is May 5, 2026.

MDXG past earnings growth

How has MDXG's earnings growth performed historically?

Company
-22.22%
Industry
59.12%
Market
90.49%
MDXG's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
MDXG's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

MDXG earnings history

Current Revenue
$389.4M
Current Earnings
$30.7M
Current Profit Margin
7.9%
MDXG's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

MDXG Return on Equity

Current Company
12.9%
Current Industry
-5.4%
Current Market
12.2%
MDXG's Return on Equity (12.9%)... subscribe to Premium to read more.
High Return on Equity Performance

MDXG Return on Assets

Current Company
9.7%
Current Industry
-14.9%
MDXG is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MDXG announces earnings.

MDXG Return on Capital Employed

Current Company
15.1%
Current Industry
-10%
MDXG has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MDXG vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MDXG$54.47M$30.70M-36.45%$0.21
TECX-$69.37M-$74.15MN/A-$4.05
AGMB-$72.32M-$72.73MN/A-$166.54
RIGL$131.56M$367.02M+1,960.61%$20.40
TRDA-$138.73M-$143.75MN/A-$3.47
View Top Biotech Stocks

MDXG earnings dates

Next earnings date
May 5, 2026

Mimedx Group Earnings Reports & History FAQ

What were Mimedx Group's earnings last quarter?

On MDXG's earnings call on Invalid Date, Mimedx Group (NASDAQ: MDXG) reported Q1 2026 earnings per share (EPS) of -$0.07, up 240% year over year. Total MDXG earnings for the quarter were -$10.86 million. In the same quarter last year, Mimedx Group's earnings per share (EPS) was $0.05.

If you're new to stock investing, here's how to buy Mimedx Group stock.

When does Mimedx Group report earnings?

The next MDXG earnings date is Invalid Date. Add MDXG to your watchlist to be reminded of Mimedx Group's next earnings date.

Is Mimedx Group profitable or losing money?

As of the last Mimedx Group earnings report, Mimedx Group is currently profitable. Mimedx Group's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $30.70 million, a 23.6% decrease year over year.

What was MDXG's earnings growth in the past year?

As of Mimedx Group's earnings date in Invalid Date, Mimedx Group's earnings has grown -22.22% year over year. This is 81.35 percentage points lower than the US Biotechnology industry earnings growth rate of 59.12%. MDXG earnings in the past year totalled $30.70 million.

What are Mimedx Group's earnings expectations?

The current EPS estimate for Mimedx Group's earnings report in Invalid Date is $0.06.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.